Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 3
2004 1
2005 4
2006 1
2007 2
2008 5
2009 1
2010 4
2011 1
2012 3
2013 4
2014 2
2015 1
2016 3
2017 4
2018 3
2019 6
2020 9
2021 13
2022 13
2023 21
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes: A sub-analysis of the PROTECT trial.
Kusunose K, Imai T, Tanaka A, Doi M, Koide Y, Fukumoto K, Kadokami T, Ohishi M, Teragawa H, Ohte N, Yamada H, Sata M, Node K; PROTECT investigators. Kusunose K, et al. Among authors: teragawa h. J Cardiol. 2024 Feb 18:S0914-5087(24)00020-0. doi: 10.1016/j.jjcc.2024.02.002. Online ahead of print. J Cardiol. 2024. PMID: 38378130
Vasospastic Angina in a Young Woman: A Case Report.
Yoshida M, Orita Y, Oshita C, Uchimura Y, Teragawa H. Yoshida M, et al. Among authors: teragawa h. Cureus. 2023 Nov 29;15(11):e49640. doi: 10.7759/cureus.49640. eCollection 2023 Nov. Cureus. 2023. PMID: 38033437 Free PMC article.
JCS/CVIT/JCC 2023 guideline focused update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction.
Hokimoto S, Kaikita K, Yasuda S, Tsujita K, Ishihara M, Matoba T, Matsuzawa Y, Mitsutake Y, Mitani Y, Murohara T, Noda T, Node K, Noguchi T, Suzuki H, Takahashi J, Tanabe Y, Tanaka A, Tanaka N, Teragawa H, Yasu T, Yoshimura M, Asaumi Y, Godo S, Ikenaga H, Imanaka T, Ishibashi K, Ishii M, Ishihara T, Matsuura Y, Miura H, Nakano Y, Ogawa T, Shiroto T, Soejima H, Takagi R, Tanaka A, Tanaka A, Taruya A, Tsuda E, Wakabayashi K, Yokoi K, Minamino T, Nakagawa Y, Sueda S, Shimokawa H, Ogawa H; Japanese Circulation Society and Japanese Association of Cardiovascular Intervention and Therapeutics and Japanese College of Cardiology Joint Working Group. Electronic address: jcsGL@j-circ.or.jp. Hokimoto S, et al. Among authors: teragawa h. J Cardiol. 2023 Oct;82(4):293-341. doi: 10.1016/j.jjcc.2023.06.009. J Cardiol. 2023. PMID: 37597878 Free article. No abstract available.
Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
Tanaka A, Shibata H, Imai T, Yoshida H, Miyazono M, Takahashi N, Fukuda D, Okada Y, Teragawa H, Suwa S, Kida K, Moroi M, Taguchi I, Toyoda S, Shimabukuro M, Tanabe K, Tanaka K, Nangaku M, Node K; FIVE-STAR trial investigators. Tanaka A, et al. Among authors: teragawa h. Cardiovasc Diabetol. 2023 Jul 31;22(1):194. doi: 10.1186/s12933-023-01928-y. Cardiovasc Diabetol. 2023. PMID: 37525257 Free PMC article. Clinical Trial.
104 results